Sensorion announces $71.9m reserved offering to expand gene therapy pipeline
Sensorion has announced a €60m ($71.9m) reserved offering through the issuance of 214,285,714 new ordinary shares at €0.28 per share …
Post
-
-
FDA grants breakthrough status to Biogen’s litifilimab for CLE
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Biogen’s litifilimab (BIIB059) for cutaneous lupus erythematosus …
-
Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership
In a move that continues a recent bolstering of its gene therapy pipeline, Eli Lilly has signed a global research …
-
The importance of real-world evidence in transforming healthcare decision-making
Over the last 20 years, US healthcare has shifted to a value-based system, with payers and healthcare providers being challenged …
-
Advancing pharma fulfilment in 2026: is your software up to the challenge?
Pharmaceutical and healthcare fulfilment operations are under enormous pressure, with a need to navigate multiple supply chain challenges. Scalable systems are …
-
The beginning of the end: Eliquis sales forecast to plummet as EU patent expiry nears
This year, sales of Bristol Myers Squibb’s (BMS) and Pfizer’s drug Eliquis (apixaban) are projected to decline by 15.2% due …
-
CMS selects next batch of 15 high-cost medicines for third negotiation cycle
The Centers for Medicare & Medicaid Services (CMS) has announced the next 15 high-cost medicines up for price negotiations under the …
-
FDA accepts Otsuka’s centanafadine application for ADHD treatment
The US Food and Drug Administration (FDA) has accepted for priority review Otsuka Pharmaceutical’s new drug application (NDA) submitted for …
-
Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies
Insilico Medicine has entered a strategic partnership with Qilu Pharmaceutical and its subsidiary Shanghai Qilu Pharmaceutical Research Center on drug …
-
UK and certain European countries lose WHO’s measles-free status
The UK is one of several European countries to lose its status as measles-free amid a diminishing uptake of the …
-
Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline
Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, expanding its pipeline in rare and severe liver diseases. Agreed in December …
-
FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s
Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the supplemental biologics …
-
Internet of Medical Things beats AI as top ranked growth driver among life science CEOs
A new report has revealed that 83% of life sciences CEOs view Internet of Medical Things (IoMT) devices as the …
-
UK biotechs suffered restricted financing in 2025
Both the amount of equity financing and venture capital attracted by UK biotechs dropped in 2025, compounding concerns for the …
-
MSD ends takeover talks with Revolution Medicines
Merck & Co (MSD) is no longer in talks to acquire oncology biotech Revolution Medicines after negotiations hit a stumbling …
